147 related articles for article (PubMed ID: 32386081)
1. Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort.
Kanamori T; Sanada M; Ri M; Ueno H; Nishijima D; Yasuda T; Tachita T; Narita T; Kusumoto S; Inagaki A; Ishihara R; Murakami Y; Kobayashi N; Shiozawa Y; Yoshida K; Nakagawa MM; Nannya Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Horibe K; Handa H; Ogawa S; Iida S
Br J Haematol; 2020 Dec; 191(5):755-763. PubMed ID: 32386081
[TBL] [Abstract][Full Text] [Related]
2. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
Chng WJ; Santana-Dávila R; Van Wier SA; Ahmann GJ; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Jacobus S; Blood E; Oken MM; Henderson K; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
Leukemia; 2006 May; 20(5):807-13. PubMed ID: 16511510
[TBL] [Abstract][Full Text] [Related]
4. An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics.
Hoang PH; Cornish AJ; Sherborne AL; Chubb D; Kimber S; Jackson G; Morgan GJ; Cook G; Kinnersley B; Kaiser M; Houlston RS
Blood Cancer J; 2020 Oct; 10(10):101. PubMed ID: 33057009
[TBL] [Abstract][Full Text] [Related]
5. [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].
Decaux O; Lodé L; Minvielle S; Avet-Loiseau H
Rev Med Interne; 2007 Oct; 28(10):677-81. PubMed ID: 17559979
[TBL] [Abstract][Full Text] [Related]
6. 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
Lee J; Smith D; Rabin N; Tobias J; Yong K
Hematol Oncol; 2016 Sep; 34(3):165-70. PubMed ID: 26073569
[TBL] [Abstract][Full Text] [Related]
7. [Advances in multiple myeloma molecular biology research].
Hanamura I
Rinsho Ketsueki; 2019; 60(9):1236-1242. PubMed ID: 31597849
[TBL] [Abstract][Full Text] [Related]
8. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
10. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
[TBL] [Abstract][Full Text] [Related]
11. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
12. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
[TBL] [Abstract][Full Text] [Related]
13. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
14. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
15. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
Ji M; Jang S; Lee JH; Seo EJ
Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
[No Abstract] [Full Text] [Related]
16. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
17. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
[TBL] [Abstract][Full Text] [Related]
18. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.
Greenberg AJ; Philip S; Paner A; Velinova S; Badros A; Catchatourian R; Ketterling R; Kyle RA; Kumar S; Vachon CM; Rajkumar SV
Blood Cancer J; 2015 Jan; 5(1):e271. PubMed ID: 25555162
[TBL] [Abstract][Full Text] [Related]
19. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
[TBL] [Abstract][Full Text] [Related]
20. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]